CITIUS ONCOLOGY, INC.
For the period ended Sep 30, 2025. Filed Dec 23, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Dec 23, 2025
CTOR$0.55+7.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Changes in Stockholders’ Equity
| Preferred Stock · Common Stock · Additional Paid-In · Accumulated · Total Stockholders’ | ||||||||
|---|---|---|---|---|---|---|---|---|
| Shares · Amount · Shares · Amount · Capital · Deficit · Equity | ||||||||
| Balance, September 30, 2023 | - | $ | - | 67,500,000 | $6,750 | $43,658,750 | $(18,129,840) | $25,535,660 |
| Capital contributions by parent | - | - | - | - | 37,008,905 | - | 37,008,905 | |
| Stock-based compensation expense | - | - | - | - | 7,498,817 | - | 7,498,817 | |
| Merger, net of transaction costs of $2,358,780 | - | - | 4,052,402 | 405 | (2,754,701) | - | (2,754,296) | |
| Net loss | - | - | - | - | - | (21,148,747) | (21,148,747) | |
| Balance, September 30, 2024 | - | - | 71,552,402 | 7,155 | 85,411,771 | (39,278,587) | 46,140,339 | |
| Issuance of common stock in July 2025 registered direct offering, net of costs of $1,453,012 | - | - | 6,818,182 | 682 | 7,546,306 | - | 7,546,988 | |
| Issuance of common stock in September 2025 registered direct offering, net of costs of $1,380,146 | - | - | 5,142,858 | 514 | 7,619,340 | - | 7,619,854 | |
| Stock-based compensation expense | - | - | - | - | 8,320,419 | - | 8,320,419 | |
| Net loss | - | - | - | - | - | (24,761,369) | (24,761,369) | |
| Balance, September 30, 2025 | - | $ | - | 83,513,442 | $8,351 | $108,897,836 | $(64,039,956) | $44,866,231 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.